Ascendis Pharma A/S Q1 2023 Earnings Report $131.35 -2.16 (-1.62%) (As of 12/3/2024 ET) Ascendis Pharma A/S EPS ResultsActual EPS-$2.12Consensus EPS -$2.84Beat/MissBeat by +$0.72One Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual Revenue$36.04 millionExpected Revenue$24.53 millionBeat/MissBeat by +$11.51 millionYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ1 2023Date4/27/2023TimeN/AConference Call ResourcesPress ReleaseASND Earnings HistoryPowered by WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Ascendis Pharma A/S Earnings HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNovember 25, 2024 | americanbankingnews.comAscendis Pharma: Strategic Expansion and Product Launches Drive Future Growth, Outperform Rating ReaffirmedNovember 19, 2024 | markets.businessinsider.comCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…December 4, 2024 | Crypto 101 Media (Ad)Ascendis Pharma price target lowered to $153 from $160 at TD CowenNovember 15, 2024 | markets.businessinsider.comAscendis Pharma Reports Strong Q3 2024 ResultsNovember 15, 2024 | markets.businessinsider.comAscendis Pharma’s Strategic Advances and Yorvipath Launch Position Stock for Growth: Buy Rating Affirmed by AnalystNovember 15, 2024 | markets.businessinsider.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
